GLPG2737, a CFTR Inhibitor, Prevents Cyst Growth in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease
Our findings in preclinical models provide evidence of the therapeutic potential of CFTR inhibition and its possible combination with tolvaptan. The present work shows that targeting CFTR is a valid strategy to slow ADPKD progression. .
Authors
- Peter C. Harris (ORCID: https://orcid.org/0000-0002-5304-6593)
- Daisy Liekens
- Carole Delachaume
- Katleen Verdonck
- S. Meurisse
- Daniel Comas
- Florence Anquetil (ORCID: https://orcid.org/0000-0001-9256-8979)
- N. Vandeghinste
- Vincent Dumont (ORCID: https://orcid.org/0000-0002-2893-5479)
- Jinghua Hu (ORCID: https://orcid.org/0000-0001-9635-9779)
- Roland Blanqué
- Thierry Christophe
- Jessica Nakhlé (ORCID: https://orcid.org/0000-0003-2123-5776)
- T. Pradeepa Robert
- Katja Conrath (ORCID: https://orcid.org/0009-0003-0703-2830)
- Yan Huang
- Valérie Salgues
Institutions
- Mayo Clinic (US)
- Galapagos (France) (FR)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- Galapagos (Belgium) (BE)
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1159/000545614
- Citations
- 1
- Primary Topic
- Genetic and Kidney Cyst Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Galápagos